Menu
Close
Stories & News
Resources
Stay Informed
x
Stay Informed
November 2, 2021
Pfizer Inc. (NYSE: PFE) reported financial results for third quarter 2021 and raised 2021 guidance for revenues and Adjusted diluted EPS reflecting the net impact of its updated expectations for contributions to 2021 performance from both Comirnaty, the Pfizer-BioNTech SE (BioNTech) COVID-19 vaccine, as well as its business excluding Comirnaty.
Additionally, Pfizer published this morning on its website the third-quarter 2021 earnings presentation and accompanying prepared remarks from management as well as the quarterly update to its R&D pipeline.
Please see below for earnings highlights and visit Pfizer’s Investors site for more information.
Forward-looking statements included herein are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. We encourage you to read our reports filed with the U.S. Securities and Exchange Commission (SEC), including the sections captioned “Risk Factors” and “Forward Looking Information and Factors that May Affect Future Results,” for a description of such substantial risks and uncertainties. These reports are available at pfizer.com and the SEC’s website.
Copyright © 2002 – 2025 Pfizer Investor Insights All rights reserved. This information—including product information—is intended only for residents of the United States. The products discussed herein may have different labeling in different countries. This website contains certain information about Pfizer, but may not contain all information that is material to Pfizer.